SCHEMBL2267922

SCHEMBL2267922

CC(=O)OSN1C(=O)C=CC1=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 2/20 0.39
GSK3B P49841 2/20 0.39
MGLL Q99685 2/20 0.39
ALDH1A1 P00352 2/20 0.34
BLM P54132 2/20 0.34
CYP1A2 P05177 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
WRN Q14191 1/20 0.34
HIF1A Q16665 1/20 0.34
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
GMNN O75496 1/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
THPO P40225 1/20 0.30
PMP22 Q01453 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5577325 0.71 MGLL (0.43) GSK3AGSK3BMGLLALDH1A1BLM
SCHEMBL208215 0.65 ALDH1A1 (0.38) GSK3AGSK3BMGLLALDH1A1BLM
SCHEMBL16256331 0.63
SCHEMBL2756782 0.62 ALDH1A1 (0.64) GSK3AGSK3BMGLLALDH1A1BLM
SCHEMBL9311835 0.61 ALDH1A1 (0.56) GSK3AGSK3BMGLLALDH1A1BLM
SCHEMBL709406 0.61 MGLL (0.42) GSK3AGSK3BMGLLALDH1A1BLM
SCHEMBL720720 0.61 MGLL (0.43) GSK3AGSK3BMGLLALDH1A1BLM
SCHEMBL11571457 0.60 MGLL (0.32) GSK3AGSK3BMGLL
SCHEMBL8097898 0.60 GAA (0.34) GSK3AGSK3BMGLLALDH1A1BLM
SCHEMBL976025 0.59 MGLL (0.72) GSK3AGSK3BMGLLALDH1A1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003078-B2 Targeted MR imaging agents BARNES-JEWISH HOSPITAL (US) 2011-08-23 US disclosed
US-20080247943-A1 Blood Clot-Targeted Nanoparticles KEREOS, INC. 2008-10-09 US disclosed
EP-1539252-A4 BLOOD CLOT-TARGETED NANOPARTICLES BARNES JEWISH HOSPITAL (US) 2008-03-12 EP disclosed
WO-2007115115-A2 TARGETED MR IMAGING AGENTS KEREOS, INC. (US) 2007-10-11 WO disclosed
US-20070237721-A1 TARGETED MR IMAGING AGENTS KEREOS, INC. 2007-10-11 US disclosed
EP-1539252-A2 BLOOD CLOT-TARGETED NANOPARTICLES Barnes-Jewish Hospital (US) 2005-06-15 EP disclosed
WO-2004017907-A2 BLOOD CLOT-TARGETED NANOPARTICLES BARNES-JEWISH HOSPITAL (US) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247943-A1 Blood Clot-Targeted Nanoparticles FGB, PLAT, PLG GSK3A 4643/4885GSK3B 4578/4885MGLL 164/4885
US-20070237721-A1 TARGETED MR IMAGING AGENTS TSPO, ARNT, RXFP4 GSK3A 4222/4885GSK3B 4220/4885MGLL 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.